IFRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
InflaRx NV is not a good immediate buy for a beginner long-term investor with $50,000-$100,000 to deploy right now. The stock has some positive medium-term interest from analysts and hedge funds, but the current setup is technically stretched and the company is still loss-making with minimal revenue. Given the pre-market weakness and overbought condition, the better call is to hold and wait rather than buy at this moment.
IFRX is in an overall bullish trend based on moving averages, with SMA_5 > SMA_20 > SMA_200 and a positive, expanding MACD histogram. However, RSI_6 is 85.195, which is deeply overbought and suggests the recent move may be extended. Pre-market price is 2.02, down 2.42%, and it is sitting just below the R1 resistance at 2.077, with the next resistance at 2.312. Support is below at 1.697 and 1.317. The technical picture shows momentum, but the current entry is late and short-term downside risk is elevated.
["Oppenheimer initiated coverage with an Outperform rating and a $5 price target.", "Guggenheim kept a Buy rating, even after lowering its target to $14 from $22, signaling continued bullish long-term conviction.", "Hedge funds are buying aggressively, with buying amount up 425.33% over the last quarter.", "Nasdaq compliance was regained, removing an overhang related to minimum bid price requirements.", "Izicopan remains viewed as the main value driver, supported by promising Phase 2a basket study data and advancement into Phase 2b in hidradenitis suppurativa."]
["Pre-market price is down 2.42%, showing near-term weakness.", "RSI is extremely overbought at 85.195, which often precedes pullbacks.", "The company posted zero revenue in the latest quarter and remains deeply unprofitable.", "Net income was -10,642,392 in 2025/Q4, indicating continued losses.", "Historical pattern analysis suggests a negative forward drift over the next week and month.", "No recent AI Stock Picker or SwingMax signal is present to support an immediate entry."]
In 2025/Q4, InflaRx reported revenue of 0, which was flat year over year and shows no commercial growth yet. Net income improved year over year to -10.64 million, and EPS improved to -0.15, but the business is still unprofitable. The latest quarter season is 2025/Q4. The financial picture is improving on the loss side, but there is still no meaningful top-line traction.
Analyst sentiment remains constructive overall, but price targets have come down recently. On 2026-04-24, Oppenheimer initiated coverage with an Outperform rating and a $5 target, down from $7, citing izicopan as the key value driver. On 2026-03-20, Guggenheim lowered its target to $14 from $22 while keeping a Buy rating, still calling the stock significantly undervalued. Wall Street’s pro case is the pipeline and possible undervaluation; the con case is the reduced targets, clinical execution risk, and the lack of current revenue.
